Trivascular Technologies (NASDAQ: TRIV) and Amedica (NASDAQ:AMDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
This is a breakdown of current recommendations for Trivascular Technologies and Amedica, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Trivascular Technologies and Amedica’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
62.5% of Amedica shares are held by institutional investors. 0.1% of Amedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Trivascular Technologies and Amedica’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amedica||$15.23 million||0.67||-$14.76 million||($1.93)||-1.75|
Trivascular Technologies has higher earnings, but lower revenue than Amedica. Trivascular Technologies is trading at a lower price-to-earnings ratio than Amedica, indicating that it is currently the more affordable of the two stocks.
Amedica beats Trivascular Technologies on 9 of the 9 factors compared between the two stocks.
About Trivascular Technologies
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Receive News & Ratings for Trivascular Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies and related companies with MarketBeat.com's FREE daily email newsletter.